Kornimate/medical-research-clean huggingface dataset:
a study of familial and genetic aspects of adult t-cell: leukemia/lymphoma , tropical spastic paraparesis, and infective dermatitis

Conditions: HTLV-I

Summary: doctors of the university of west indies, the caribbean epidemiology center (carec) and the national cancer institute have been studying the epidemiology of htlv-i and its role in the etiology and pathogenesis of adult t-cell leukemia/lymphoma (alt), and aggressive t-cell lymphoma. the purpose of the current study is to evaluate familial and genetic aspects of atl and its relationship to two other htlv-i related conditions, htlv-i associated myelopathy also known as tropical spastic paraparesis (ham/tsp), and infective dermatitis. enrollment of infective dermatitis cases was recently added and the disease entity is thought to be a harbinger for later development of either atl or ham/tsp. the purpose of this study is to interview patients with these conditions and perform laboratory studies (specifically, hla and other viral or genetic studies) to better understand these diseases and their relationship to the htlv-1 virus and the family history and genetic factors that may be involved as well.

doctors of the university of west indies, the caribbean epidemiology center (carec) and the national cancer institute have been studying the epidemiology of htlv-i and its role in the etiology and pathogenesis of adult t-cell leukemia/lymphoma (alt), and aggressive t-cell lymphoma. the purpose of the current study is to evaluate familial and genetic aspects of atl and its relationship to two other htlv-i related conditions, htlv-i associated myelopathy also known as tropical spastic paraparesis (ham/tsp), and infective dermatitis. enrollment of infective dermatitis cases was recently added and the disease entity is thought to be a harbinger for later development of either atl or ham/tsp. the purpose of this study is to interview patients with these conditions and perform laboratory studies (specifically, hla and other viral or genetic studies) to better understand these diseases and their relationship to the htlv-1 virus and the family history and genetic factors that may be involved as well.

Eligibility criteria:
* inclusion criteria: all cases of atl and tsp which satisfy the case definitions above. cases will be selected regardless of htlv-1 sero-status. exclusion criteria: cases who have none of the first three priority family members available i.e. parents, offspring and siblings, will be excluded from this study however summary data will be maintained.

Keywords: htlv-i
the effectiveness of chuna maintenance therapy for chronic bothersome neck pain

Conditions: Neck Pain; Chronic Pain

Summary: this study is a pragmatic randomized controlled study that assessed 250 subjects complaining of chronic bothersome neck pain with mild discomfort in a 1:1 ratio: chuna maintenance therapy group (125 subjects, 1 time/2 weeks, total 20 weeks) and lifestyle management \& self-exercise group (125 subjects, exercise method education 1 time/4 weeks, total 20 weeks).


Eligibility criteria:
* inclusion criteria: 1. aged 19 or older but under 70. 2. neck pain with pain duration of 12 months or longer 3. nrs of neck pain over the past month is 2 or more but less than 4 4. patients who have agreed to trial participation and provided written informed consent * exclusion criteria: 1. patients diagnosed with serious pathology(s) which may cause neck pain (e.g. spinal metastasis of tumor(s), acute fracture, spinal dislocation) 2. patients with progressive neurologic deficit or severe neurologic symptoms such as spinal cord injury 3. patients whose pain is due to soft tissue disease not the spine (e.g. tumors, fibromyalgia, rheumatoid arthritis, gout) 4. patients with other chronic disease(s) which may interfere with treatment effect, safety, or interpretation of outcome (e.g. stroke and myocardial infarction, kidney disease, diabetic neuropathy, dementia, epilepsy) 5. patients currently taking steroids, immunosuppressants, medicine for mental illness or other medication(s) that may interfere with study results 6. pregnant patients or patients with plans of pregnancy or lactating patients 7. patients within 3 months after cervical surgery 8. patients with experience of participating in another clinical study within 1 month or plan to participate in another clinical study during the study participation and follow-up period within 6 months from the participation date 9. patients having difficult to completing the written informed consent 10. patients who are deemed unsuitable by the researchers

Keywords: chuna therapy manual therapy chronic neck pain
pharmacokinetic (pk) and tolerance study of natroba topical suspension in pediatrics with an active head lice infestation

Conditions: Pediculosis

Summary: a pharmacokinetic and tolerance study of natroba (spinosad) topical suspension, 0.9% in pediatric subjects 6 months to 4 years of age with an active head lice infestation.

a postmarketing requirement protocol, multicenter, open-label study in pediatric subjects 6 months to 4 years of age with an active head lice infestation designed to determine the topical absorption and safety of natroba (spinosad) topical suspension, 0.9% for a single, 10 minute treatment for spinosad (spinosyn a and spinosyn d) and benzyl alcohol.

Eligibility criteria:
inclusion criteria: 1. male or female, 6 months to 4 years of age. 2. subjects must have had an active lice infestation including live lice. 3. individuals in otherwise good general health, free of any systemic or dermatologic disorders which, in the opinion of the principal investigator or designee, would interfere with the study results or increase the risk of adverse events. 4. a parent (or guardian) must have signed an informed consent form to allow any child to participate in the study. 5. subjects must have been available to stay in the clinic for blood draws. parents or guardians must have been available to stay in the clinic, with the subject, for the entire duration of the study. 6. subjects must have had veins capable of insertion of a heplock catheter or withstanding multiple blood draws as determined by the principal investigator or qualified phlebotomist. 7. normal values (at screening) for serum chemistry and hematology for subjects, unless the principal investigator or qualified medical designee determined that the abnormal value was not clinically significant. exclusion criteria: 1. history of irritation or sensitivity to pediculicide or hair care products or ingredients. 2. history of known allergy or sensitivity to topical anesthetics including lidocaine and prilocaine. 3. history of allergy or sensitivity to heparin. 4. systemic diseases that could have interfered with the results of this study as determined by the principal investigator or designee. 5. any condition or illness that, in the opinion of the investigator or designee, may have compromised the objective of the protocol or the safety of the subject. 6. the use of antibiotics or other systemic medications within 2 weeks of the screening visit, which in the opinion of the investigator or designee could have interfered with the outcome of the study. 7. participation in a previous drug study within the past 30 days. 8. individuals with any visible skin/scalp condition (other than from an active lice infestation) at the treatment site which would have interfered with the evaluations according to the opinion of the investigator or designee. 9. parents or guardians who, in the opinion of the investigator, did not understand their child's requirements for study participation and/or may be likely to exhibit poor compliance.

Keywords: pediculosis capitis head lice
post-authorization long-term safety surveillance on antihypertensive treatment with kanarb® (fimasartan)

Conditions: Essential Hypertension

Summary: evaluated the incidence and characteristics of adverse events during the treatment for kanarb tablet.

this study is designed to evaluate the incidence and characteristics (profile, relationship to the study drug, severity, and outcome) of adverse events (aes) observed during 1-year treatment with kanarb tablet® (fimasartan)

Eligibility criteria:
inclusion criteria: 1. patients with essential hypertension 2. taking kanarb tablet® (fimasartan) as prescribed previously (within 1 month) or newly 3. male and female adults aged 20 years or older 4. voluntarily provided a written consent to participate in the study exclusion criteria: 1. patients with hypersensitivity to this drug or the ingredients of this drug 2. pregnant or breast-feeding women 3. patients on renal dialysis 4. patients with moderate to severe hepatic impairment 5. patients with biliary atresia 6. genetic disorders such as galactose intolerance, lapp lactase deficiency, or glucose-galactose malabsorption 7. patients considered inappropriate for taking kanarb tablet® (fimasartan) by investigator 8. clinically significant abnormal liver function (ast, alt ≥2 x upper limit of normal (uln); tb ≥1.5 uln)

Keywords: hypertension fimasartan
a single-blind, randomized, controlled clinical study of flash stimulation therapy in parkinson's disease

Conditions: Parkinson&#39;s Disease

Summary: the aim of this study was to evaluate the effect of flash stimulation therapy on the function of the cerebral glymphatic system and efficacy of improving symptoms in pd patients.

each subject will receive eeg recordings for two consecutive nights starting at 21:00. participants will undergo baseline functional magnetic resonance imaging (fmri). subsequently, one week of flash stimulation therapy (jk-pmeg2700k light modulation glasses \[light source\]) was started, using flash stimulation between 20:00 and 21:00. after the 7-day flash stimulation treatment, a second round of clinical evaluation and fmri will be performed.

Eligibility criteria:
inclusion criteria: 1. pd patients who meet the diagnostic criteria of the international movement disorders association (mds), between the ages of 50 and 70 years, the course of disease ≤5 years, and the hoehn \& yahr stage ≤3; 2. anti-pd drugs were taken regularly for at least one month before screening, and symptoms were stable; 3. the fixed bedtime in the past month is between 9:00 p.m. and 1:00 a.m., and the total sleep time is ≥6 hours; 4. have the ability to understand and voluntarily sign informed consent; 5. have good compliance and are willing to complete all follow-up required by this program. exclusion criteria: 1. secondary insomnia: including sleep disorders (restless leg syndrome, periodic limb movement disorder, sleep-related breathing disorders, etc.), physical diseases, mental disorders, psychoactive substance abuse; 2. suffering from photosensitive dermatitis, epilepsy and other diseases that are not suitable for flash stimulation; 3. alcohol, coffee, or drug abusers in the past 6 months; 4. mental illness: such as anxiety, depression, schizophrenia and post-traumatic stress disorder caused by insomnia; 5. used drugs or health products that regulate sleep function or affect sleep within 14 days before enrollment or less than 5 drug half-lives; 6. taking drugs that may impair cognitive ability, such as anticholinergic drugs, memory enhancing drugs, etc., within 7 days before enrollment; 7. the subject is unable to complete the test or follow-up; 8. suffering from other neurodegenerative diseases; 9. there are endoplants in the body that cannot be examined by mri; 10. inability to lie flat; 11. other situations in which the researcher considers it inappropriate to participate in the study.

Keywords: parkinson&#39;s disease
validation of bd onclarity™ hpv assay with preservcyt® -ascus samples

Conditions: Uterine Cervical Neoplasm

Summary: the purpose of the study is to compare the results of the becton dickinson (bd) human papilloma virus (hpv) assay on the viper lt instrument from liquid-based cytology media diluted in hpv diluent to adjudicated histology results from biopsy.


Eligibility criteria:
inclusion criteria: * females who are greater than or equal to 21 years of age, * subjects with a ascus (atypical squamous cells - undetermined significance) cytology result, * females who provide informed consent exclusion criteria: * known pregnant * prior complete or partial hysterectomy involving removal of cervix * conization, leep, cervical laser surgery or cryosurgery on the cervix has been performed in the last twelve months * colposcopy clinic referral patients
application of dce-mri based on 4d freebreathing in predicting the efficacy of immune and targeted therapy in lung cancer

Conditions: Lung Cancer

Summary: this study aims to address the challenge of predicting the efficacy of targeted and immunotherapy in lung cancer patients. by utilizing two dce-mri images-one before treatment and one after one treatment cycle-along with the patients' clinical and pathological information, we aim to achieve accurate prediction of the therapeutic efficacy of targeted and immunotherapy in lung cancer patients.


Eligibility criteria:
inclusion criteria: 1. tumor size greater than 2 cm 2. age between 18 and 75 years exclusion criteria: 1. presence of mri contraindications (e.g., metal implants, pacemaker implantation, etc.) 2. allergy to gadolinium contrast agents 3. lesions difficult to delineate on images due to conditions such as atelectasis or diffuse lesions
a study to evaluate the effect of carbetocin on the qt/qtc interval in healthy subjects

Conditions: Postpartum Hemorrhage

Summary: carbetocin is an oxytocin receptor agonist that selectively binds to receptors in the smooth muscle of the uterus, stimulates rhythmic contractions of the uterus, increases the frequency of existing contractions, and raises the tone of the uterine musculature. carbetocin is approved in \>100 countries for the prevention of postpartum hemorrhage due to uterine atony in women following cesarean or vaginal delivery. per regulatory requirements, the current trial will evaluate the effects of high clinical exposure of carbetocin on the qt interval corrected for heart rate (qtc) as measured by ecg in healthy men and women.


Eligibility criteria:
inclusion criteria: * healthy, adult, male or female subjects, 18-45 years of age, inclusive, at the screening visit. * body mass index (bmi) ≥ 18.5 and ≤29.9 kg/m2 at the screening visit. * continuous non-smoker who has not used nicotine- or tobacco-containing products for at least 3 months prior to first dosing. exclusion criteria: * sustained supine systolic blood pressure ≥130 mmhg or \<90 mmhg, supine diastolic blood pressure ≥80 mmhg or \<50 mmhg at screening or first check-in. * history or presence of clinically significant ecg findings in the opinion of the principal investigator (pi) or designee at the screening visit or first check-in, including each of the following: * hr \ 100 bpm. * qtcf is ≥450 msec (males) or ≥460 msec (females). * qrs ≥110 msec; if ≥110 msec, result will be confirmed by a manual over read. * pr ≥200 msec. * history or presence of: * risk factors for torsades de pointes (e.g., heart failure, cardiomyopathy, family history of long qt syndrome, brugada syndrome, or sudden cardiac death). * sick sinus syndrome, second- or third-degree atrioventricular block, myocardial infarction, angina, pulmonary congestion, symptomatic or significant cardiac arrhythmia, or clinically significant conduction abnormalities. * clinically significant abnormal laboratory assessments including hypokalemia, hypercalcemia, or hypomagnesemia, in the opinion of the pi or designee.
caracterisation of covid-19 patients hospitalized in infectious disease department

Conditions: Covid19; SARS-CoV Infection

Summary: the main objective of this cohort is to characterize covid-19 patients hospitalized in infectious disease department. the collection of clinical and biological data from start of hospitalization to long-term follow up will contribute to a better description of the patient care, to the identification of predisposition to complication related to the disease, and to the evaluation of the impact of different therapeutical strategies.


Eligibility criteria:
inclusion criteria: * age \> or = to 18 * patients hospitalised for sars-cov-2 infection confirmed by rt pcrand/or ct scan and/or serology exclusion criteria: * patients for whom sars-cov-2 infection has not been confirmed
physiological response in lung transplant recipients undergoing neurally adjusted ventilatory assist

Conditions: Work of Breathing; Lung Transplant; Complications; Neurally Adjusted Ventilatory Assist; Ventilator-Induced Lung Injury

Summary: primary graft dysfunction (pgd) respresents the leading cause of mortality in early post-operative period of lung tranplantation (ltx). protective ventilatory strategy could potentially reduce the risk of pgd in these patients. neurally adjusted ventilatory assist (nava) is an assisted ventilation mode that could allow to adopt this strategy. aim of the study is to assess the feasibility of nava in the early post-ltx phase and to describe the breathing pattern and the physiological relationship between neural respiratory drive and different levels of ventilatory assist, in the absence of pulmonary vagal afferent feedback.

lung transplantation (ltx) is an important treatment option for select patients with end-stage pulmonary disease. primary graft dysfunction (pgd) is the main cause of death; in the early period following ltx a protective ventilatory strategy (tidal volume - vt of 6 ml/kg + positive end expiratory pressure) could potentially reduce the risk of pgd in these patients. neurally adjusted ventilatory assist (nava) is an assisted ventilation mode in which neural inspiratory activity is monitored through the continuous recording of electrical activity of the diaphragm (eadi). actually, guidelines about the adoption of a protective ventilatory strategy in the early post-opeartive period are lacking. nava, because of its intrinsic properties (proportionality between respiratory drive and level of assist, prevention of diaphragm atrophy), could allow to reach the afore mentioned ventilatory strategy. so, aim of the study, is the evaluation of patients' neural breathing pattern during nava, in early post-operative period of ltx

Eligibility criteria:
inclusion criteria: * age \> 18 y.o. * admission to icu for post-operative monitoring after ltx * presence of spontaneous breathing activity * sedation titrated to a target rass between 0 and -2 * written informed consent obtained exclusion criteria: * contraindication to nasogastric tube insertion (gastroesophageal surgery in the previous 3 months, gastroesophageal bleeding in the previous 30 days, history of esophageal varices, facial trauma) * increased risk of bleeding with nasogastric tube insertion, due to severe coagulation disorders and severe thrombocytopenia ( i.e., inr \> 2 and platelets count \< 70.000/mm3) * severe hemodynamic instability (noradenaline \> 0.3 μg/kg/min and/or use of vasopressin) * postoperative extracorporeal respiratory support (ecmo) * pre-operative reconditioning of the transplanted lungs by means of ex-vivo lung perfusion (evlp) * lung retransplantation * failure to obtain a stable eadi signal
triple combination therapy in type 2 diabetic patients who had inadequate glycemic control with combination therapy

Conditions: Type 2 Diabetes

Summary: to assess the efficacy of treatment with sitagliptin or dapagliflozin or lobeglitazone in type 2 diabetes mellitus patients, who had inadequate glycemic control even though use of two drug combination therapy with glimepiride and metformin.

dual combination therapy with metformin and sulphonylurea is the most commonly used combination regimen to treat patients with type 2 diabetes. but, treatment with the dual combination therapy is often unsuccessful at achieving glycaemic control in patients with type 2 diabetes. recently, various oral hypoglycemic agents were developed including dipeptidyl peptidase (dpp)-iv inhibitor, sodium-glucose cotransporter 2 (sglt2) inhibitor and new peroxisome proliferator-activated receptors (ppars) agonists. but, there have been few studies about the glucose lowering effect of these drugs in type 2 diabetes patients on the dual combination therapy with a sulfonylurea agent and metformin. hence, the researchers plan to investigate the efficacy and safety of these drugs in combination with a sulfonylurea agent and metformin in type 2 diabetic patients.

Eligibility criteria:
inclusion criteria: * 20 ≤ age \< 80 years * hba1c ≥ 7 % * combination therapy with glimepiride and metformin over 2 months. * dosage of glimepiride : 1-8mg/day * dosage of metformin : 500-2550mg/day exclusion criteria: * type 1 diabetes, gestational diabetes, or secondary forms of diabetes * contraindication to sitagliptin or dapagliflozin or lobeglitazone * pregnant or breast feeding women * medication which affect glycemic control (ex. steroid) * disease which affect efficacy and safety of drugs * any major illness (liver disease, renal failure, heart disease, cancer, etc) * not appropriate for oral antidiabetic agent

Keywords: triple combination therapy sitagliptin dapagliflozin lobeglitazone
the effect of artificial sweeteners (afs) on sweetness sensitivity, preference and brain response in adults

Conditions: Impairment of Oral Perception; Insulin Resistance

Summary: the purpose of this study is to investigate the effects of dietary exposure to artificial sweeteners on taste sensitivity, preference and brain response in adults. the investigators hypothesize that dietary exposure to artificial sweeteners (sucralose) will decrease sensitivity to taste, shift preference of sweet and savory taste to a higher dose, and reduce brain response in amygdala to sweet taste compared to sucrose.

we aim to identify neural factors that contribute to taste intensity perception in humans and to determine environmental mechanisms that contribute to variation in taste sensitivity. significant controversy surrounds the possibility that consumption of artificial sweeteners (afs) leads to weight gain. given that the five fda approved afss are found in thousands of foods (yang 2010) this marks a clear and significant gap in knowledge. our preliminary data demonstrate a 3-fold decrease in sweet taste sensitivity following consumption of a beverage sweetened with two packets of splenda for just 10 days. these data provide strong evidence that repeated exposure to sucralose reduces perception of sweet taste intensity, most likely by down-regulation of the sweet taste receptor. therefore, it is imperative that we gain a greater understanding of the physiological consequences of afs, since alterations in sweet taste perception, metabolism and brain reward that occur in response to afs exposure may promote weight gain.

Eligibility criteria:
inclusion criteria: * healthy * fluent in english * right handed exclusion criteria: * history of oral nerve damage, * presence of known taste or smell disorder, * food allergies or sensitivities (for example nuts, lactose, artificial sweeteners), * history of cns disease, * diabetes, * history of dsm-iv major psychiatric disorder, * including alcohol and substance abuse, * chronic use of medication that may affect taste, * conditions that may interfere with gustatory or olfactory perception (colds, seasonal allergies, * recent smoking history), * aberrant stimulus ratings, * contra-indication for fmri, * uncomfortable swallowing in supine position, * discomfort or anxiety associated with insertion an intravenous catheter, * regular artificial sweetener use.